Kyphon Inc

Kyphon — Merger or Acquisition (August 2007)

71 slides from Kyphon's merger presentation, Aug 9, 2007

  1. Slide 1: Kyphon Investor Overview

    Kyphon Investor Overview August 9, 2007

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements The forward-looking statements in this presentation are subject to a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking information, and are based on Kyphon’s current expectations, estimates, for

  3. Slide 3: Important Additional Information

    Important Additional Information Kyphon intends to file with the Securities and Exchange Commission (“SEC”) a proxy statement and other relevant documents in connection with the proposed acquisition. KYPHON’S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS WHEN THEY B

  4. Slide 4: Please Note

    Please Note While Kyphon has executed two definitive agreements to acquire all of the spine-related assets of Disc-O-Tech Medical Technologies, Ltd., neither of the underlying transactions has closed to date. Both transactions remain subject to clearance under the Hart-Scott-Rodino Antitrust Improve

  5. Slide 5: Kyphon at A Glance

    Kyphon at A Glance Medical device company focused on minimally invasive spine market Pioneered balloon kyphoplasty—a novel procedure for repairing vertebral compression fractures Three product platforms serve estimated $6 billion potential market – Spinal Fracture Repair & Management (~$3 billion) –

  6. Slide 6: Over a Decade of Progress

    Over a Decade of Progress 1994 – Company Founded 1996 – Company Funded 1998 – Inflatable Bone Tamps Cleared by FDA First Balloon Kyphoplasty Procedure 2002 – Successful IPO (5/17/02) 2003 – Company Surpasses $100M in Worldwide Sales 2004 – First Bone Cement Cleared by FDA for Use in Kyphoplasty 100,

  7. Slide 7: Agenda

    Agenda Kyphon vision and strategy Update on VCF management & repair franchise Spinal motion preservation franchise overview Proposed Disc-O-Tech transactions and rationale Proposed Medtronic acquisition of Kyphon Financial summary

  8. Slide 8: Focused Vision and Strategy

    Focused Vision and Strategy Vision Improve patient quality of life through revolutionizing the practice of medicine Strategy 1. Expand penetration in existing markets 2. Grow in new geographies 3. Leverage platforms through innovative new products Recent announced acquisitions consistent with vision

  9. Slide 9: Platforms for Growth: Innovative Treatments for the Aging Spine

    Platforms for Growth: Innovative Treatments for the Aging Spine Kyphon Mission Become the recognized global leader in restoring spinal function through minimally invasive therapies Spinal Fracture Management & Repair • Osteoporotic and Cancer-Related Fracture Treatment • Traumatic Fracture Fixation

  10. Slide 10: Factors Driving Spinal Market Growth

    Factors Driving Spinal Market Growth Aging population – major driver – number of people worldwide over age 60 doubling to 1.2B in 2025 Desire for active, sustained quality of life Growth in new minimally invasive procedures – this is our focus New and better implants Improvements in imaging technolo

  11. Slide 11: We Have Built Significant Capabilities

    We Have Built Significant Capabilities R&D Clinical/ Regulatory Professional Education Supply Chain Capabilities Global Sales Channel Customer Relationships IP Portfolio Reimbursement Strategic Competencies

  12. Slide 12: Track Record of Solid Execution and Results

    Track Record of Solid Execution and Results Net Sales ($M) 03 04 05 06 CAGR 52.2% $76 $131 $213 $306 $408 +33% vs. PY Pro forma Operating Margin(1-3) 03 04 05 06 (1) 2006 excludes SFAS 123(R) & Disc-O-Tech (2) 2005 excludes license payments (3) 2003 excludes lease termination charge 0% 11% 16% 21% 2

  13. Slide 13: InnoSpine, Inc.: First Move Beyond Original Focus

    InnoSpine, Inc.: First Move Beyond Original Focus January 2006 acquired InnoSpine, Inc. Novel method for diagnosing source of low back pain – injects anaesthetic, vs current procedure provokes pain – allows functional testing Leverages our sales channel and technology platform – broad potential 510(

  14. Slide 14: Agenda

    Agenda Kyphon vision and strategy Update on VCF management & repair franchise Spinal motion preservation franchise overview Proposed Disc-O-Tech transactions and rationale Proposed Medtronic acquisition of Kyphon Financial summary

  15. Slide 15: Spinal Fracture Management & Repair: Balloon Kyphoplasty

    Spinal Fracture Management & Repair: Balloon Kyphoplasty Vertebral Compression Fracture Balloon-Assisted Deformity Correction Cavity Creation Internal Fixation Minimally invasive correction of spinal deformity Single-level procedure takes less than one hour > 70 unique products

  16. Slide 16: What Sets Balloon Kyphoplasty Apart?

    What Sets Balloon Kyphoplasty Apart? Balloon kyphoplasty is a treatment that: 1. Helps to correct vertebral body deformity 2. Offers low complication rate 3. Improves and maintains quality of life

  17. Slide 17: Improved Patient Quality of Life – Real Stories

    Improved Patient Quality of Life – Real Stories Joan Schoengold Age: 82 Diagnosis: Osteoporotic fracture “I felt better right away. It’s like a miracle.” Christine Siegel Age: 57 Diagnosis: Multiple myeloma (cancer) induced fracture “I was bedridden for over a year, on opioids for pain. After the pr

  18. Slide 18: Significant VCF Market Opportunity for Balloon Kyphoplasty

    Significant VCF Market Opportunity for Balloon Kyphoplasty Spinal Compression Fractures* Osteoporosis Cancer Trauma Total Annual $2,200M $350M $450M $3.0B Market (700K)(150K)(100K)(950K) Potential Kyphoplasty Fractures 105K 9K 1K 115K Treated Penetration Today: ~12% * Diagnosed fractures in United S

  19. Slide 19: Strong Sales Channel Momentum

    Strong Sales Channel Momentum Global Kyphon sales reps U.S. = 296 Int’l = 122 04 05 06 Global specialists trained in balloon kyphoplasty Available to train ~20,000 3,900 5,600 8,000 10,400 04 05 06 2Q U.S. hospital customers 1,100 1,794 1,864 Potential customers ~3,300 04 05 06 2Q

  20. Slide 20: Balloon Kyphoplasty Benefits Sustained for Over Years

    Balloon Kyphoplasty Benefits Sustained for Over 2 Years Normalized results from 100 patients followed in published multicenter prospective study Bodily pain – improved 257% Role physical – improved 461% (Ability to perform daily activities) Patient satisfaction with Kyphoplasty procedure (Median) 10

  21. Slide 21: Extensive Balloon Kyphoplasty Clinical Trial Program

    Extensive Balloon Kyphoplasty Clinical Trial Program Clinical Trial Strategy Expand usage in new procedural areas such as cancer and trauma Support global expansion and entry into Japan Availability of Level-1 procedural & healthcare utilization cost data TRIAL FREE CAFE BEST JAPAN KAVIAR Condition

  22. Slide 22: Expanding Our Global Reach

    Expanding Our Global Reach Europe Over 50% of international revenue from one country – Germany, followed reimbursement Reimbursement progressing in all countries – UK, positive NICE recommendation Japan Substantial market opportunity – >500,000 VCFs per year – Conservative care only approved treatme

  23. Slide 23: In Short for Balloon Kyphoplasty: The Runway for Growth is Long

    In Short for Balloon Kyphoplasty: The Runway for Growth is Long % of diagnosed fractures treated today with balloon kyphoplasty 12% % of US radiologists trained ~30% % of hospitals in US penetrated ~50% Years Europe is behind the U.S. in adopting procedure 2-3 years Anticipated market entry in Japan

  24. Slide 24: Agenda

    Agenda Kyphon vision and strategy Update on VCF management & repair franchise Spinal motion preservation franchise overview Proposed Disc-O-Tech transactions and rationale Proposed Medtronic acquisition of Kyphon Financial summary

  25. Slide 25: Acquisition Overview: St. Francis Medical Technologies, Inc.

    Acquisition Overview: St. Francis Medical Technologies, Inc. Novel treatment for symptoms of lumbar spinal stenosis (LSS) X-STOP® Interspinous Process Decompression (IPD®) System – first approved interspinous process device in the U.S. – estimated 15,000 X-STOP® devices implanted worldwide (through

  26. Slide 26: Acquisition Highlights: St. Francis Medical Technologies, Inc.

    Acquisition Highlights: St. Francis Medical Technologies, Inc. Price up to $725M –$ 525M at closing – additional revenue-based contingent payments of up to $200M Impact on GAAP earnings – dilutive in 2007 – significantly accretive in 2008 Closed on January 18, 2007 Financed through cash on hand, syn

  27. Slide 27: A First-Line Surgical Option for LSS Patients

    A First-Line Surgical Option for LSS Patients X-STOP® IPD® System is an alternative to conventional spinal stenosis surgery following failed conservative treatment Shown to be safe and effective in clinical studies Typically implanted during a short procedure using local anesthesia Proven to signifi

  28. Slide 28: Significant LSS Market Opportunity for X-STOP Solution

    Significant LSS Market Opportunity for X-STOP® Solution LSS patients diagnosed (1) 1.4 million Non-operative care 500,000 30% (2) Surgical decompression 140,000 50% (2) Do not seek treatment 760,000 150,000 70,000 Initial Annual U.S. Market Opportunity Patients 220,000 Implant ASP $4,500 Avg. Implan

  29. Slide 29: What is Lumbar Spinal Stenosis?

    What is Lumbar Spinal Stenosis? Narrowing of spinal canal Impinges on nerves in the spinal canal or nerves exiting to legs Pain and weakness in legs that limits daily activities Symptom relief: More space for nerve roots Extension Symptoms exacerbated Less space for nerve roots Flexion Symptoms reli

  30. Slide 30: Gap in Traditional Treatment Options

    Gap in Traditional Treatment Options Spinal Stenosis Continuum of Care Mild Moderate Severe Epidural Injection Lifestyle limitations Physical therapy Temporary relief Treats symptoms GAP Laminectomy Invasive, open surgery Tissue disruption/removal Hospital stay, extended recovery Weakens spine In so

  31. Slide 31: X-STOP Device Fills the Gap

    X-STOP® Device Fills the Gap Combines the Best of Both Worlds Spinal Stenosis Continuum of Care Mild Moderate Severe Epidural Injection Lifestyle limitations Physical therapy Temporary relief Treats symptoms Risk profile similar to non-op care Significant improvement in treatment success vs. non-op

  32. Slide 32: X-STOP IPD Procedure

    X-STOP® IPD® Procedure Dilate interspinous ligament Determine implant size Insert implant into interspinous space Secure adjustable wing Procedure requires minimal incision Tissue expander guides oval spacer through interspinous space Retains all spinal bones and ligaments Procedure is reversible

  33. Slide 33: X-STOP IPD Procedure Benefits

    X-STOP® IPD® Procedure Benefits Motion-preserving – No removal of bone and connective tissue – No simultaneous fusion required Addresses underlying cause – Limits extension – Prevents compression of nerves Preserves future treatment options – Reversible – Can be easily explanted

  34. Slide 34: Key Clinical Publications

    Key Clinical Publications Article Description Clinical Outcomes Zucherman – Spine 2005 IDE 2-year outcomes: X-STOP® IPD® procedure vs. Non-op Hsu – J Neurosurg Spine 2006 QOL 2-year outcomes after X-STOP® IPD® procedure Anderson – J Neurosurg Spine 2006 X-STOP® implant device in spondylolisthesis (G

  35. Slide 35: X-STOP IPD Procedure: IDE Pivotal Trial Design

    X-STOP® IPD® Procedure IDE Pivotal Trial Design Zucherman – Spine 2005: Prospective, randomized, multicenter clinical trial – Led to approval of the X-STOP® IPD® implant in U.S. X-STOP® IPD® procedure vs. non-operative care – 191 patients (100 X-STOP® IPD® implants, 91 non-op) – Non-op was mostly ep

  36. Slide 36: Significant Improvement vs Non-operative Care

    X-STOP® IPD® Procedure Significant Improvement vs Non-operative Care % of patients with clinically meaningful improvement X-STOP® Device N=73 Non-Operative Care N=66 64% 17% Symptom Severity 66% 17% Physical Function 73% 24% Patient Satisfaction Zurich Claudication Questionnaire (ZCQ) Criteria 56% 6

  37. Slide 37: Low Complication Rate: Operation Is Not Near the Nerves

    X-STOP® IPD® Procedure—Low Complication Rate: Operation Is Not Near the Nerves Back Spinal canal, where nerves reside, exit Abdomen

  38. Slide 38: Low Complications

    Low Complications IDE Study: X-STOP® IPD® Procedure Group* Operative-Site Related (post surgery/discharge) Incisional pain (1) Hematoma (1)‡ Wound swelling (1) ‡ Wound dehiscence (1) ‡ Implant Related Implant dislodgement (1) ‡ Implant malpositioned (1) Spinous process fracture (1) ‡ Resulted in a s

  39. Slide 39: Radiographic Outcomes

    Radiographic Outcomes IDE Study No significant difference between control and X-STOP® IPD® procedure groups at 12 and 24 months in: – Disc height – Curvature of spine – Angulation of spine – Degree of spondylolisthesis X-STOP® implant maintained distraction in 96% of all levels measured (defined as

  40. Slide 40: X-STOP IPD Procedure Success: Outcomes May Be Similar to Laminectomy

    X-STOP® IPD® Procedure Success Outcomes May Be Similar to Laminectomy % of patients expressing satisfaction with improvement X-STOP® Device N=96 Laminectomy N=197 58% 55% 71% 47% 63% 59% 72% 47% Symptom Severity Physical Function Patient Satisfaction ZCQ Success (all 3 criteria) Zurich Claudication

  41. Slide 41: Studies In Progress or Planned

    X-STOP® IPD® Procedure Studies In Progress or Planned Condition of Approval Studies—United States – OUTLAST: Five-year follow-up IDE study – COAST: Post-market study of 240 additional subjects X-STOP® IPD® procedure vs. laminectomy* – Sweden – Netherlands – Norway – UK Some randomized, some not X-ST

  42. Slide 42: X-STOP IPD Procedure Summary

    X-STOP® IPD® Procedure Summary Mechanical relief of major LSS symptoms now possible Proven to achieve superior outcomes to non-operative care Associated with a low rate of complications Negligible intervertebral angle changes—i.e., no evidence of kyphosis Procedure is reversible—does not compromise

  43. Slide 43: X-STOP Device Reimbursement Established

    X-STOP® Device Reimbursement Established Inpatient facilities—FY2007 – ICD-9 code 84.58 (implantation of interspinous process decompression device) maps to DRG codes 499 or 500 – DRG payment rates of approx. $4,889 – $7,361 (non-fusion back surgery) – New technology add-on payment (up to $4,400) eff

  44. Slide 44: Sales and Marketing for X-STOP Device

    Sales and Marketing for X-STOP® Device Marketed to spine surgeons in 17 countries – targeted to same physician/surgeon base as balloon kyphoplasty Estimated 15,000 X-STOP® devices sold worldwide (through 12/31/06) – average U.S. sales price for device is $4,500; ~1.5 devices per procedure used Empha

  45. Slide 45: In Summary: X-STOP Device is an Excellent Fit

    In Summary: X-STOP® Device is an Excellent Fit Complementary growth platform that fits our mission $2+ billion potential global market opportunity Innovative solution that leverages established global sales channel Compelling clinical data compared to existing treatment alternatives Significant prog

  46. Slide 46: Next Generation Treatment Option for LSS Symptoms: Aperius PercLID System

    Next Generation Treatment Option for LSS Symptoms: Aperius™ PercLID™ System First PERCutaneous Lumbar Interspinous Decompression System Available in 4 different sizes for optimal decompression and patient sizing Ability to treat two levels of spine with single small incision CE Mark and available in

  47. Slide 47: Next Generation Treatment Option for LSS Symptoms: Aperius PercLID System

    Next Generation Treatment Option for LSS Symptoms: Aperius™ PercLID™ System Percutaneous access and implantation using image guidance Series of four access tools matched to four implant sizes Stabilizing wings deployed in situ via actuation mechanism Undeployed Deployed

  48. Slide 48: Aperius PercLID Percutaneous Access

    Aperius™ PercLID™ Percutaneous Access Access Tools Preloaded Implants

  49. Slide 49: Standing Spinal MRI

    Standing Spinal MRI Before Aperius™ Implant After Aperius™ Implant

  50. Slide 50: Clinical Trials Supporting New Indications

    Clinical Trials Supporting New Indications Spinal Motion Preservation & Disc Disease Diagnosis & Repair Clinical Trial Strategy Confirm X-STOP® IPD® PMA results & potentially expand indications Develop clinical science foundation for Aperius™ device and F.A.D.™ procedure Investigate potential of spa

  51. Slide 51: Agenda

    Agenda Kyphon vision and strategy Update on VCF management & repair franchise Spinal motion preservation franchise overview Proposed Disc-O-Tech transactions and rationale Proposed Medtronic acquisition of Kyphon Financial summary

  52. Slide 52: Overview: Disc-O-Tech Medical Technologies, Ltd.

    Overview: Disc-O-Tech Medical Technologies, Ltd. Innovative treatments for minimally invasive fusion and vertebral augmentation – B-Twin™ Expandable Spinal System – Confidence™ Cement System – SKy™ Bone Expander System Disc-O-Tech IP provides scope and breadth to existing Kyphon IP portfolio

  53. Slide 53: Transaction Highlights: Disc-O-Tech Medical Technologies, Ltd.

    Transaction Highlights: Disc-O-Tech Medical Technologies, Ltd. Two definitive agreements to acquire all Disc-O-Tech spine-related assets* Price $220M – $60M paid in Dec 2006; $40M paid in Feb 2007 – 3 annual payments of $40M each beginning in Jan 2008 – additional $20M contingent payments may be pai

  54. Slide 54: Disc-O-Tech: Growth Platform in Minimally Invasive Fusion

    Disc-O-Tech: Growth Platform in Minimally Invasive Fusion B-Twin™ Expandable Spinal System – first interbody device suitable for percutaneous stabilization of lumbar & cervical spine during a fusion procedure – stand-alone implant or in conjunction with posterior stabilization – can be performed ent

  55. Slide 55: What Is Spinal Fusion?

    What Is Spinal Fusion? “Welding” of 2 or more vertebrae with – bone graphs or device-like metal rods Fusion treats – injuries to vertebrae – protrusion, disk degeneration – abnormal curvatures (scoliosis / kyphosis) – spine problems from infections, tumors Current treatment – invasive surgery – seve

  56. Slide 56: Minimally Invasive Fusion is Attractive Segment

    Minimally Invasive Fusion is Attractive Segment 350,000 estimated lumbar spinal fusions annually in U.S. and Europe Global market opportunity of ~$1+ billion Fast growth in minimally invasive alternatives to classic fusion – less blood loss – reduced tissue & muscle trauma – lower risk of neurologic

  57. Slide 57: Disc-O-Tech: VCF Treatment

    Disc-O-Tech: VCF Treatment Confidence™ Cement System Innovative high viscosity cement injection technology Potential for reduced clinician radiation exposure Available in U.S. and international markets SKy™ Bone Expander System Fracture reduction technology CE Mark and available in international mar

  58. Slide 58: Disc-O-Tech Products Fit Our Strategy

    Disc-O-Tech Products Fit Our Strategy Directly supportive of our mission Leverages spine specialist base and direct global sales channel Complements Functional Anaesthetic Discography™ procedure Provides immediate access to international fusion markets Broadens product suite for treatment of VCFs in

  59. Slide 59: Agenda

    Agenda Kyphon vision and strategy Update on VCF management & repair franchise Spinal motion preservation franchise overview Proposed Disc-O-Tech transactions and rationale Proposed Medtronic acquisition of Kyphon Financial summary

  60. Slide 60: Transaction Overview

    Transaction Overview Consideration Transaction Value Premium to Kyphon Share Price Customary Approvals Anticipated Close $71.00 per share in cash $3.9 billion plus $320 million in payments associated with St. Francis Medical, Inc. acquisition and proposed acquisition of spine-related assets of Disc-

  61. Slide 61: Selected Precedent Transactions

    Selected precedent transactions Spine/ortho transaction comps ($ millions) Date announced Target company Acquiror Business description Transaction value (TV) TV / LTM Sales TV / FTM Sales 07/27/2007 Kyphon 1 Medtronic Medical technology for spine $4,351 9.8x 7.0x 12/18/2006 Biomet Private equity inv

  62. Slide 62: Precedent Premiums

    Precedent premiums Announced deals with US target, 2004 — Q12007, % average premium to announcement One-month premium1 Mean Median 29% 37% 38% 25% 30% 30% All M&A Technology and Healthcare M&A Medical Technology M&A Source: Public filings, equity research Premium offered to target's shareholders bas

  63. Slide 63: Medtronic at a Glance

    Medtronic at a Glance Medtronic is the global leader in medical technology—alleviating pain, restoring health, and extending life for millions of people around the world Founded in 1949, the company’s FY07 revenues were $12.3 billion Seven sectors serve estimated $80 billion potential market – Cardi

  64. Slide 64: Creating a Global Leader in Minimally Invasive Spine Market

    Creating a Global Leader in Minimally Invasive Spine Market Allows more patients of all ages to receive benefits of modern, minimally invasive spinal treatments earlier in care Combines two world-class sales organizations to better serve our patients and clinicians Extends product offerings into som

  65. Slide 65: Roadmap To Completion

    Roadmap To Completion Event Execute definitive agreement Kyphon shareholder vote Receive all regulatory clearances Close transaction Expected Timeline Completed 3-5 months First calendar quarter of 2008 Targeted in first calendar quarter of 2008

  66. Slide 66: Summary

    Summary Offers outstanding premium and immediate return on investment for shareholders Provides Kyphon with a stronger platform for growth Leverages combined organization’s world-class sales forces and expertise in developing and marketing innovative products Anticipated to close in first calendar q

  67. Slide 67: Agenda

    Agenda Kyphon vision and strategy Update on VCF management & repair franchise Spinal motion preservation franchise overview Proposed Disc-O-Tech transactions and rationale Proposed Medtronic acquisition of Kyphon Financial summary

  68. Slide 68: Financial Summary

    Financial Summary $ Million 2005 2006 Q1 2007 Q2 2007 Net Sales $ 306.1 $ 408.0 $ 128.1 $ 144.3 % Growth vs Prior Period 43% 33% 40% 43% (over Q1’06) (over Q2’06) Ratios to Net Sales Gross Profit 88% 87% 85% 87% R&D 8% 10% 8% 9% Sales & Marketing 47% 48% 48% 44% G&A 12% 15% 14% 14% Operating Expense

  69. Slide 69: Balance Sheet

    Balance Sheet $ Million 6/30/2007 Inc / (Dec) vs. 12/31/06 Cash and Investments $ 51.9 $ (30.1) Accounts Receivable $ 97.2 $ 23.3 Inventory $ 19.1 $ 6.7 All Other Assets Total Assets $ 740.4 $ 908.6 $ 479.1 $ 479.0 Liabilities $ 572.5 $ 487.6 Stockholders Equity Liabilities + Equity $ 336.1 $ 908.6

  70. Slide 70: Leader in Revolutionizing MI Spine

    Leader in Revolutionizing MI Spine Track record of profitably growing rapidly in underpenetrated multibillion $ markets Creating new markets and redefining existing markets – supported by a significant and expanding IP portfolio Executing growth strategy to develop & acquire earlier-stage therapies

  71. Slide 71: Kyphon Investor Overview

    Kyphon Investor Overview August 9, 2007

Kyphon — Merger or Acquisition (August 2007) on 6ix